Author

C. Seguin-Devaux

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Research Focus:host-pathogen & immune response· 3 Assay:proteomics· 3 Research Focus:drug response / drug discovery· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Organism:mouse· 1

Frequent Co-Authors

G. Iserentant· 3 shared J.-Y. Servais· 3 shared B. Brandus· 2 shared J. Zimmer· 2 shared M. Moutschen· 2 shared R. Schober· 2 shared X. Dervillez· 2 shared D. Perez-Bercoff· 1 shared

Activity by Year

2022-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

G. Iserentant

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Complement-Activating Multimeric Immunotherapeutic Complexes for HER2-breast cancer immunotherapy

C. Seguin-Devaux, B. Brandus, J.-M. Plesseria, G. Iserentant, J.-Y. Servais, G. Kanli, I. Behrmann, J. Zimmer, J. H. COHEN, X. Dervillez

This study develops and tests CoMiX immunotherapeutics that activate complement to kill HER2-positive breast cancer cells, showing significant tumor growth inhibition in xenograft models.

bioRxiv · Feb 2, 2024 · PreprintImmunology

Natural Killer activating Multimeric Immunotherapeutic compleXes (NaMiX) induce cytotoxic activity and killing of HIV-1 infected cells

R. Schober, B. Brandus, T. Laeremans, G. Iserentant, G. Dessilly, J. Zimmer, M. Moutschen, J. L. Aerts, X. Dervillez, C. Seguin-Devaux

This study develops NaMiX, multimeric immunotherapeutics targeting NK cell checkpoints, which enhance NK cell cytotoxicity against HIV-1 infected cells and reduce viral DNA in mice.

bioRxiv · Nov 11, 2022 · PreprintImmunology

Vaccine- and BTI-elicited pre-Omicron immunity more effectively neutralizes Omicron sublineages BA.1, BA.2, BA.4 and BA.5 than pre-Omicron infection alone

E. Santos da Silva, J.-Y. Servais, M. Kohnen, V. Arendt, G. Gilson, T. Staub, C. Seguin-Devaux, D. Perez-Bercoff

This study compares neutralization of Omicron sublineages by sera from vaccinated, infected, and hybrid immune individuals, finding that hybrid immunity provides the best cross-neutralization.

bioRxiv · Oct 24, 2022 · PreprintImmunology

The anti-caspase 1 inhibitor VX-765 reduces immune activation, CD4+ T cell depletion, viral load and total HIV-1 DNA in HIV-1 infected humanized mice

M. Amand, P. Adams, R. Schober, G. Iserentant, J.-Y. Servais, M. Moutschen, C. Seguin-Devaux

bioRxiv · Sep 1, 2022Immunology